SPONTAN® Prescribed to First Patient Under TGA Authorised Prescriber Scheme

16 August 2024

Highlights:

- **First select group of patients receive SPONTAN® under the Therapeutic Goods Administration (TGA) Authorised Prescriber Scheme (APS), marking a significant step forward in the market introduction strategy:**
  - **APS provides faster patient access to SPONTAN**
  - **This allows for broader patient access for patients with a particular medical condition rather than on a case-by-case basis**
- **Authorised Prescribers are specialists and experienced practitioners in their relevant therapeutic areas which helps with treatment outcomes**
- **SPONTAN provides an unmet, fast-acting, on-demand erectile dysfunction (ED) treatment for patients suffering from erectile dysfunction**

LTR Pharma Limited (**ASX:LTP**) ("**LTR Pharma**", "the **Company**") is pleased to announce a significant advancement in the rollout of SPONTAN® following its recent introduction under the Special Access Scheme ("**SAS**"). SPONTAN has now been prescribed to the first patients under the Therapeutic Goods Administration's ("**TGA**") Authorised Prescriber Scheme ("**APS**").

The Authorised Prescriber Scheme represents a major step forward in SPONTAN's market introduction strategy. Unlike the case-by-case approach of the SAS, the APS allows registered medical practitioners to prescribe SPONTAN to a broader class of patients with erectile dysfunction, streamlining access for those who may benefit from this innovative treatment.

Leading this milestone prescription under the APS is Professor Eric Chung, an internationally renowned expert in the field of urology and men's health. Professor Chung's involvement underscores the growing recognition of SPONTAN's potential in addressing unmet needs in erectile dysfunction treatment.

LTR Pharma Chief Scientific Advisor, Professor Eric Chung said: *"The Authorised Prescriber Scheme allows us to offer SPONTAN to a wider range of patients who may benefit from its rapid onset of action. This innovative nasal spray has the potential to significantly improve quality of life for men struggling with ED and offers a new treatment option, particularly for those seeking a more spontaneous solution."*

LTR Pharma Chairman, Mr. Lee Rodne said: "*The authorisation of SPONTAN under the Authorised Prescriber Scheme represents an important milestone for LTR Pharma. It emphasises the pressing need for a faster-acting erectile dysfunction treatment option and highlights SPONTAN's capacity to fulfil a significant unmet need for an on-demand ED solution. This scheme enables authorised healthcare professionals to obtain meaningful, hands-on experience with SPONTAN in real-world settings."*

SAS and APS

Following our initial announcement of LTR's Key Opinion Leader ("**KOL**") strategy, we are pleased to report that Professor Eric Chung, an internationally renowned urological surgeon and expert in male sexual health, is now prescribing SPONTAN to select patients under the TGA's Authorised Prescriber Scheme. This marks a significant

milestone in our KOL-led approach to introducing SPONTAN to the market. Professor Chung's involvement enables us to gather valuable real-world data and raise awareness within the medical community. His expertise and experience will be instrumental in demonstrating SPONTAN's potential to address the unmet need for a fast-acting, on-demand treatment for erectile dysfunction.

Authorised Prescriber Scheme

The TGA Authorised Prescriber Scheme allows registered medical practitioners to prescribe unapproved therapeutic goods to a class of patients with a particular medical condition without needing individual patient approvals. This significant development aligns with the Company's strategic approach to introducing SPONTAN through a carefully controlled, KOL-driven pathway. Under the Authorised Prescriber Scheme, designated medical practitioners can supply SPONTAN to patients who have not responded to approved treatments, thereby addressing unmet medical needs determined by these authorised healthcare professionals.

-Ends-

This announcement has been approved by the Board of Directors.

About LTR Pharma

LTR Pharma is focused on improving men's health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships across multiple age brackets. LTR Pharma's lead product SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body, supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.

For further information please contact:

Haley Chartres
Media Relations
haley@hck.digital

Peter McLennan
Investor Relations
investors@ltrpharma.com